Challenges and opportunities in high-risk patients undergoing TAVI - EuroPCR 2021

Coronary access after TAVI, a growing need - EuroPCR 2021Подробнее

The conundrum of antithrombotic therapy in atrial fibrillation patients undergoing TAVI-EuroPCR 2022Подробнее

Challenges with re-accessing the coronaries after TAVI - EuroPCR 2019Подробнее

Hemodynamics and minimalist TAVI - how does it fit? - EuroPCR 2022Подробнее

New, novel Navitor™ TAVI valve with active paravalvular leak-sealing technology - EuroPCR 2021Подробнее

Optimise your TAVI patient's outcomes: implementing the Edwards benchmark programme - EuroPCR 2021Подробнее

Latest on TAVI in complex bicuspid lesions - EuroPCR 2023Подробнее

For High Operative Risk Patients, TAVR is Now an OpportunityПодробнее

Efficient TAVI in the context of expanding indications - EuroPCR 2021Подробнее

Treating bicuspid patients, sizing algorithms - EuroPCR 2021Подробнее

How to overcome the most clinically relevant challenges in TAVI - EuroPCR 2024Подробнее

Improving your patient's outcomes with the Edwards Benchmark program - EuroPCR 2021Подробнее

Empowering DES performance in complex patients to maximise efficacy and safety outcomes - #EuroPCRПодробнее

Double jeopardy: coronary disease in patients undergoing TAVI - EuroPCR 2022Подробнее

Atrial Fibrillation and Challenges in the TAVR PatientПодробнее

SURTAVI: SAVR or TAVI for a patient at high risk for stroke? EuroPCR 2017 Hot LineПодробнее

What are the challenges for TAVI in bicuspid disease? - EuroPCRПодробнее

Introducing Navitor: a new TAVI solution - EuroPCR 2021Подробнее

NOTION-2: TAVI vs. SAVR in younger low-risk patients with severe tricuspid/bicuspid aortic stenosisПодробнее